- LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer.
- [No author given]
- Merck.com . News releases. 2022 Dec 21.
- Press release
- Free Full Text
•• Press release: Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer. (AstraZeneca. Media.)
- Update on US regulatory priority review of Lynparza in combination with abiraterone in metastatic castration-resistant prostate cancer.
- Kemp A.
- AstraZeneca. Media. Press Releases. 2022 Dec 15.
- Press release
- Free Full Text